EverGlade Consulting

🚨

The BioStabilization Systems (BoSS) program is seeking breakthrough approaches in cell preparation (TA1) and bioprocessing systems (TA2) that can maintain cell potency and expand access to advanced therapies.

🗓️ Solution summaries due:
TA1/TA2: Feb. 19, 2026
IV&V Partner: Apr. 17, 2026

Learn what ARPA-H is looking for and how EverGlade can support your submission strategy: https://hubs.ly/Q03XbZnK0

🚨 New BARDA Funding Opportunity to Advance Next-Gen Immune Assays

The ASSURE program was recently released under RRPV to accelerate the development of innovative, multiplexed immune assays that more accurately characterize immune responses to vaccines, infections and emerging threats.

The solicitation places strong emphasis on clinical utility, scalability, and commercialization potential.

📅 Abstracts due Dec. 18, 2025

Learn more about ASSURE’s requirements and how EverGlade can help you develop a competitive submission: https://hubs.ly/Q03Vc_x50

We were pleased to attend ARPA-H’s GIVE Proposer’s Day last week, where program leadership highlighted the agency's focus on expanding access to RNA-based genetic medicines through distributed, resilient manufacturing. ⬇️

GIVE represents a meaningful step toward ensuring genetic therapies are more accessible, affordable, and available to all who need them.

It was a great opportunity to join innovators and researchers committed to advancing a more adaptable biomanufacturing ecosystem.

Preparing a submission for ARPA-H GIVE? Our experts can help ensure your strategy and materials are polished, competitive, and aligned with agency requirements: https://hubs.ly/Q03TN9Pz0